Multivariate analysis | ||
Hazard ratio (95% CI) | p-value | |
Sex (male versus female) | 0.92 (0.62–1.36) | 0.67 |
Number of injections of nivolumab | 0.95 (0.00–0.997) | 0.036 |
Performance status at nivolumab initiation (0–1 versus 2–4) | 0.999 (0.60–1.65) | 0.998 |
Performance status at first tumour evaluation (0–1 versus 2–4) | 1.60 (0.97–2.65) | 0.065 |
Post-nivolumab treatment (yes versus no) | 2.55 (1.68–3.89) | <0.0001 |
Histology (squamous versus nonsquamous) | 1.47 (0.96–2.27) | 0.079 |
Bold type represents statistical significance.